As of 2024-12-13, the EV/EBITDA ratio of Fulcrum Therapeutics Inc (FULC) is -11.17. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FULC's latest enterprise value is 157.69 mil USD. FULC's TTM EBITDA according to its financial statements is -14.11 mil USD. Dividing these 2 quantities gives us the above FULC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 9.8x | 8.5x |
| Forward P/E multiples | 13.1x - 19.1x | 16.3x |
| Fair Price | (2.09) - (1.23) | (1.90) |
| Upside | -148.9% - -128.8% | -144.5% |
| Date | EV/EBITDA |
| 2024-12-12 | -10.26 |
| 2024-12-11 | -11.17 |
| 2024-12-10 | -10.33 |
| 2024-12-09 | -10.18 |
| 2024-12-06 | -10.10 |
| 2024-12-05 | -9.49 |
| 2024-12-04 | -8.27 |
| 2024-12-03 | -9.26 |
| 2024-12-02 | -9.68 |
| 2024-11-29 | -9.57 |
| 2024-11-27 | -9.95 |
| 2024-11-26 | -8.42 |
| 2024-11-25 | -8.00 |
| 2024-11-22 | -7.27 |
| 2024-11-21 | -6.20 |
| 2024-11-20 | -6.28 |
| 2024-11-19 | -6.36 |
| 2024-11-18 | -6.43 |
| 2024-11-15 | -6.34 |
| 2024-11-14 | -7.54 |
| 2024-11-13 | -8.46 |
| 2024-11-12 | -8.77 |
| 2024-11-11 | -8.77 |
| 2024-11-08 | -8.19 |
| 2024-11-07 | -8.15 |
| 2024-11-06 | -7.96 |
| 2024-11-05 | -7.54 |
| 2024-11-04 | -7.31 |
| 2024-11-01 | -7.12 |
| 2024-10-31 | -6.93 |
| 2024-10-30 | -7.24 |
| 2024-10-29 | -7.24 |
| 2024-10-28 | -7.24 |
| 2024-10-25 | -7.05 |
| 2024-10-24 | -7.24 |
| 2024-10-23 | -7.27 |
| 2024-10-22 | -7.81 |
| 2024-10-21 | -8.27 |
| 2024-10-18 | -8.27 |
| 2024-10-17 | -8.42 |
| 2024-10-16 | -8.69 |
| 2024-10-15 | -8.84 |
| 2024-10-14 | -8.50 |
| 2024-10-11 | -8.15 |
| 2024-10-10 | -7.35 |
| 2024-10-09 | -7.89 |
| 2024-10-08 | -8.38 |
| 2024-10-07 | -8.50 |
| 2024-10-04 | -9.45 |
| 2024-10-03 | -8.86 |